|
Low-density lipoprotein cholesterol (LDL-C) and blood pressure measures can remain controlled in most patients discharged from a cardiac disease management program, according to a randomized study in August’s American Journal of Managed Care.
Ranbaxy Laboratories Limited has received approval from the FDA for its abbreviated new drug application to market and manufacture Ramipril 5-mg and 10-mg capsules.
|
AstraZeneca and Abbott have extended their co-promotional agreement for Trilipix (fenofibric acid), and submitted a new drug application (NDA) to the FDA for Certriad.
Cerenis Therapeutics, a pharmaceutical company developing HDL-related compounds for the treatment of cardiovascular and metabolic diseases, has licensed intellectual property supporting an HDL-therapy based investigational treatment of aortic valve stenosis (AVS).
|